Shu-Hui Chuang

Shu-Hui Chuang is a Scientist II in In vivo Pharmacology at Sage Therapeutics since August 2021, focusing on developing innovative animal models and assays for CNS disease therapeutic targets. Previous experience includes roles as a Scientist Consultant and Postdoctoral Researcher at National Taiwan University, where research centered on the effects of positive allosteric modulators of GABA-A receptors and the mechanisms of action in cerebellar neural circuits. As a Senior Fellow at the University of Washington, Shu-Hui Chuang designed experiments to assess the therapeutic efficacy of cannabidiol in a mouse model of Dravet Syndrome. A PhD candidate at Texas A&M University, work involved translational research on drug therapies for epilepsy. Earlier research assistance at National Taiwan University explored the role of CBP phosphorylation in learning and memory. Educational qualifications include a PhD in Neuroscience and Experimental Therapeutics from Texas A&M University, a Master's degree in Physiology from National Cheng Kung University, and a Bachelor's degree in Microbiology and Immunology from National Chiayi University.